Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study. [electronic resource]
Producer: 20190415Description: 1491-1496 p. digitalISSN:- 1433-7339
- Aged
- Antineoplastic Agents -- adverse effects
- Carcinoma, Renal Cell -- drug therapy
- Carnitine -- therapeutic use
- Dietary Supplements
- Fatigue -- chemically induced
- Female
- Humans
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Mind-Body Therapies
- Pilot Projects
- Sunitinib -- adverse effects
- Surveys and Questionnaires
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.